Statistics

Total Visits

Views
Long-term (52-week) results of a phase 3, randomized, controlled trial of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis (PALACE 1)69

Select a period of time:

Number of views in the range

Views
Long-term (52-week) results of a phase 3, randomized, controlled trial of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis (PALACE 1)16

Views

Views
November 202512
December 20251
January 20260
February 20260
March 20262
April 20260
May 20261
Download CSV file
 untranslated
 untranslated

Top country views

Views
Mexico9
United States4
Argentina1
Brazil1
Finland1
 

Top cities views

Views
Mexico City6
Helsinki1
Laferrere1
Leesburg1
Registro1
Santa Clara1